Human Pathology
Volume 41, Issue 11 , Pages 1617-1623 , November 2010

Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification

  • Semir Vranic, MD

      Affiliations

    • Department of Pathology, Clinical Center of the University of Sarajevo, Bosnia and Herzegovina, 71000
    • Department of Pathology, Creighton University Medical Center, Omaha, NE 68178, USA
    • ,
  • Snjezana Frkovic-Grazio, MD, PhD

      Affiliations

    • Department of Pathology, Institute of Oncology, Ljubljana, Slovenia
    • ,
  • Janez Lamovec, MD

      Affiliations

    • Department of Pathology, Institute of Oncology, Ljubljana, Slovenia
    • ,
  • Fadila Serdarevic, MD, MPH

      Affiliations

    • Institute of Epidemiology and Biostatistics, Sarajevo University School of Medicine, Bosnia and Herzegovina, 71000
    • ,
  • Olga Gurjeva, MD, PhD

      Affiliations

    • Emergency Cardiology Department, Ukrainian Strazhesko Institute, Kiev, Ukraine
    • ,
  • Juan Palazzo, MD

      Affiliations

    • Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
    • ,
  • Nurija Bilalovic, MD, PhD

      Affiliations

    • Department of Pathology, Clinical Center of the University of Sarajevo, Bosnia and Herzegovina, 71000
    • ,
  • Lisa M.J. Lee, PhD

      Affiliations

    • Department of Pathology, Creighton University Medical Center, Omaha, NE 68178, USA
    • ,
  • Zoran Gatalica, MD, DSc

      Affiliations

    • Department of Pathology, Creighton University Medical Center, Omaha, NE 68178, USA
    • Corresponding Author InformationCorresponding author.

Received 15 February 2010 ,Revised 24 April 2010 ,Accepted 30 April 2010.

References 

  1. Millar BA, Kerba M, Youngson B, Lockwood GA, Liu FF. The potential role of breast conservation surgery and adjuvant breast radiation for adenoid cystic carcinoma of the breast. Breast Cancer Res Treat. 2004;87:225–232
  2. Azoulay S, Laé M, Fréneaux P, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol. 2005;18:1623–1631
  3. Mastropasqua MG, Maiorano E, Pruneri G, et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol. 2005;18:1277–1282
  4. Magkou C, Nakopoulou L, Zoubouli C, et al. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res. 2008;10:R49
  5. Viale G, Rotmensz N, Maisonneuve P, et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 2009;116:317–328
  6. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006;208:495–506
  7. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol. 2007;25:4057–4065
  8. Nielsen KV, Ejlertsen B, Møller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol. 2008;47:725–734
  9. Celis JE, Cabezon T, Moreira JM, et al. Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort. Mol Oncol. 2009;3:220–237
  10. Honma N, Sakamoto G, Akiyama F, et al. Breast carcinoma in women over the age of 85: distinct histological pattern an androgen, oestrogen, and progesterone receptor status. Histopathology. 2003;42:120–127
  11. Fritz P, Cabrera CM, Dippon J, et al. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res. 2005;7:R374–R384
  12. Sandri MI, Hochhauser D, Ayton P, et al. Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer. 1996;73:1518–1524
  13. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145
  14. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101:644–650
  15. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008;26:4869–4874
  16. Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol. 2009;22:1044–1048
  17. World Health Organization Classification of Tumours. In:  Tavassoli FA,  Devilee P editor. Pathology and genetics of tumours of the breast and female genital organs. Lyon, France: IARC Press; 2003;p. 44–45
  18. Kasami M, Olson SJ, Simpson JF, Page DL. Maintenance of polarity and a dual cell population in adenoid cystic carcinoma of the breast: an immunohistochemical study. Histopathology. 1998;32:232–238
  19. Kleer CG, Oberman HA. Adenoid cystic carcinoma of the breast: value of histologic grading and proliferative activity. Am J Surg Pathol. 1998;22:569–575
  20. Shin SJ, Rosen PP. Solid variant of mammary adenoid cystic carcinoma with basaloid features. A study of nine cases. Am J Surg Pathol. 2002;26:413–420
  21. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141–150
  22. Page DL. Adenoid cystic carcinoma of breast, a special histopathologic type with excellent prognosis. Breast Cancer Res Treat. 2005;93:189–190
  23. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235–244
  24. Sarnaik AA, Meade T, King J, et al. Adenoid Cystic Carcinoma of the Breast: A Review of a Single Institution's Experience. Breast J. 2009;[Epub ahead of print]
  25. Soon SR, Yong WS, Ho GH, Wong CY, Ho BC, Tan PH. Adenoid cystic breast carcinoma: a salivary gland-type tumour with excellent prognosis and implications for management. Pathology. 2008;40:413–415
  26. Arpino G, Clark GM, Mohsin S, Bardou VJ, Elledge RM. Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. Cancer. 2002;94:2119–2127
  27. Peters GN, Wolff M. Adenoid cystic carcinoma of the breast. Report of 11 new cases: review of the literature and discussion of biological behavior. Cancer. 1983;52:680–686
  28. Vranic S, Bilalovic N, Lee LM, Kruslin B, Lilleberg SL, Gatalica Z. PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney. Hum Pathol. 2007;38:1425–1431
  29. Aleskandarany MA, Rakha EA, Ahmed MA, et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat. 2009;[Epub ahead of print]
  30. Sinn HP, Lehnert T, Otto HF. Adenoid cystic cancer of the breast. Case report and meta-analysis of the literature. Chirurg. 1993;64:198–202
  31. McClenathan JH, de la Roza G. Adenoid cystic breast cancer. Am J Surg. 2002;183:646–649
  32. Leeming R, Jenkins M, Mendelsohn G. Adenoid cystic carcinoma of the breast. Arch Surg. 1992;127:233–235
  33. Crabb SJ, Cheang MC, Leung S, et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 2008;8:249–256
  34. Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14:8010–8018
  35. Rydén L, Jirström K, Haglund M, Stål O, Fernö M. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat. 2010;120:490–498
  36. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–5374
  37. Matte C, Gilbert JA, Blair HA, et al. Molecular analysis of KIT and epidermal growth factor receptor in adenoid cystic carcinoma of the breast. Mod Pathol. 2008;21(Suppl. 1):46A;[abstract]
  38. Defaud-Hénon F, Tunon-de-Lara C, Fournier M, et al. Adenoid cystic carcinoma of the breast: clinical, histological and immunohistochemical characterization. Ann Pathol. 2010;30:7–16
  39. Bhargava R, Gerald WL, Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGF-activating mutations. Mod Pathol. 2005;18:1027–1033
  40. Cho EY, Choi YL, Han JJ, Kim KM, Oh YL. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathol Int. 2008;58:17–25
  41. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs. 2009;20:851–855
  42. Hoadley KA, Weigman VJ, Fan C, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 2007;8:258
  43. Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, Larsimont D. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?. Eur J Cancer. 2008;44:2791–2798
  44. Tanner M, Isola J, Wiklund T, et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol. 2006;24:2428–2436
  45. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008;100:14–20
  46. Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008;111:27–44
  47. Trendell-Smith NJ, Peston D, Shousha S. Adenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteins. Histopathology. 1999;35:241–248
  48. Crisi GM, Marconi S, Makari-Judson G, Goulart RA. Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol. 2005;124:733–739
  49. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 1993;170:31–35
  50. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract. 1997;193:753–758
  51. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21:488–492
  52. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32
  53. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2009;15:1133–1139

☆ Dr Semir Vranic was a research fellow at Creighton University Medical Center, Omaha, NE, and had been supported by a UICC American Cancer Society Beginning Investigators Fellowship (ACSBI) (ACS/08/004) funded by the American Cancer Society.

PII: S0046-8177(10)00163-2

doi: 10.1016/j.humpath.2010.04.013

Human Pathology
Volume 41, Issue 11 , Pages 1617-1623 , November 2010

Article Tools

* Image Usage & Resolution